HIMSS Analytics: Room for improvement for portals

Laura Pedulli | | Health Exec | Precision Medicine

Health IT executives are not enthused about their organizations' current patient portals, according to an Essentials Brief published by HIMSS Analytics.

This conclusion is among many in HIMSS Analytics’ 2014 Patient Portal Study, which reflects insights from healthcare IT executives across the U.S. and incorporates data from the HIMSS Analytics Database. Other key findings in the study:

  • IT executive indicate there is much room for improvement for portals
  • Patient portals typically come from the EMR vendor currently used by the organization
  • Cultural issues within organizations are a major challenge to overall patient engagement initiatives

“Patient engagement is more than just today’s hot topic-–it is foundational to the future of healthcare,” said HIMSS Analytics Research Director Brendan FitzGerald, in a statement. The study “is the first in our series of Briefs dedicated to patient engagement, and we wanted to go beyond the statistics and delve into the executive mindset.”

Learn more. 

Laura Pedulli

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.